Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 11/20 | 0.37 |
| ▸ | MAOB | P27338 | 8/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | MPL | P40238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376047 | 0.88 | CYP2C9 (0.40) | KCNJ1MAOAMAOBHTR1A | |
| SCHEMBL12409386 | 0.85 | MAOB (0.35) | KCNJ1MAOAMAOBHTR1A | |
| SCHEMBL12375894 | 0.85 | RARB (0.41) | KCNJ1MAOAMAOBGRM2MPL | |
| SCHEMBL12375905 | 0.83 | MAOA (0.41) | KCNJ1MAOAMAOBHTR2AHTR1A | |
| SCHEMBL12376015 | 0.82 | RARB (0.36) | MPL | |
| SCHEMBL12376050 | 0.80 | MAOA (0.40) | KCNJ1MAOAMAOBHTR1A | |
| SCHEMBL12376067 | 0.80 | MAOA (0.40) | KCNJ1MAOAMAOB | |
| SCHEMBL12375890 | 0.80 | MPL (0.37) | MAOAGRM2HTR2AMPL | |
| SCHEMBL12375877 | 0.79 | MAOA (0.45) | MAOAMAOBHTR1A | |
| SCHEMBL12376054 | 0.79 | MPL (0.37) | MAOAGRM2HTR2AMPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-08-11 | — | — | US | disclosed |
| US-7951305-B2 | Compound having hydrocoumarin skeleton, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090267026-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090267026-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | HCN2, PIEZO1, TRPV4 | KCNJ1 2572/4885MAOA 4598/4885MAOB 4652/4885 |
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, HCN2, HCN1 | KCNJ1 1251/4885MAOA 4053/4885MAOB 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.